Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.

Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4.

2.

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT.

N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.

3.

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):56i-67i. Epub 2007 Apr 12.

PMID:
17599426
4.

Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):44i-55i. Epub 2007 Apr 16.

PMID:
17599425
5.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):4i-20i. Epub 2007 Apr 12. Review.

PMID:
17599424
6.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
7.

Diabetic dyslipidemia.

Chahil TJ, Ginsberg HN.

Endocrinol Metab Clin North Am. 2006 Sep;35(3):491-510, vii-viii. Review.

PMID:
16959582
8.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
9.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
10.

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

Jones PH, Davidson MH.

Am J Cardiol. 2005 Jan 1;95(1):120-2.

PMID:
15619408
11.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
12.

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF.

J Clin Pharmacol. 2004 Sep;44(9):1054-62.

PMID:
15317833
13.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

14.
15.
16.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.

Lancet. 2003 Jun 14;361(9374):2005-16.

PMID:
12814710
17.

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW.

Arch Intern Med. 2002 Dec 9-23;162(22):2597-604.

PMID:
12456232
18.

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute.

Circulation. 2002 Aug 20;106(8):1024-8. No abstract available.

19.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.

JAMA. 2001 May 16;285(19):2486-97. No abstract available.

PMID:
11368702
20.

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Bezafibrate Infarction Prevention (BIP) study.

Circulation. 2000 Jul 4;102(1):21-7.

Supplemental Content

Support Center